NDAORALTABLET
Approved
Feb 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRINZIDE is a fixed-dose combination tablet containing lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) approved by the FDA in 1989. It is indicated for hypertension management in patients who require dual antihypertensive therapy. The combination works synergistically to reduce blood pressure through ACE inhibition and diuretic mechanisms.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team focus shifting toward generic transition and legacy portfolio management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRINZIDE offers exposure to mature portfolio management, generic transition strategy, and cost-containment initiatives rather than novel drug development. Career advancement here depends on maximizing post-LOE value and executing authorized generic or lifecycle extension strategies.
Brand ManagerField Sales Representative
Worked on PRINZIDE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.